Robert W. Baird Keep on with Their Maintain Ranking for Tandem Diabetes Care By


Jeff Johnson, an analyst at Robert W. Baird, on Thursday maintained a hold rating for Tandem Diabetes Care (NASDAQ 🙂 and set a price target of $ 105, approximately 24.79% above its current share price of $ 84.14 .

Johnson expects Tandem Diabetes Care to achieve earnings per share (EPS) of $ 0.27 in the second quarter of 2021.

The current consensus among 7 TipRanks analysts is a moderate buy rating for shares of Tandem Diabetes Care with an average price target of USD 126.29.
Analysts’ price targets range from a high of $ 150 to a low of $ 102.

In its most recent earnings report, released on December 31, 2020, the company posted quarterly sales of $ 168.07 million and net income of $ 18.66 million. The company’s market capitalization is $ 5.26 billion.

According to, Robert W. Baird’s analyst Jeff Johnson is currently rated 5 stars on a 0 to 5 star ranking with an average return of 29.9% and a success rate of 69.54%.

Tandem Diabetes Care, Inc. designs, develops, and markets products for people with insulin-dependent diabetes. Its flagship, the t: slim X2 insulin delivery system, works as a small insulin pump. The company was founded on January 27, 2006 by Paul M. DiPerna and is headquartered in San Diego, CA.

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media assumes no liability for any loss or damage caused by reliance on the information such as data, offers, charts and buy / sell signals contained on this website. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.